Abivax SA Sponsored ADR $ABVX Shares Sold by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. lowered its stake in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 5.4% in the fourth quarter, HoldingsChannel reports. The firm owned 691,973 shares of the company’s stock after selling 39,550 shares during the quarter. Abivax makes up approximately 8.3% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.’s holdings, making the stock its 2nd largest holding. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.’s holdings in Abivax were worth $93,316,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in ABVX. UBS Group AG boosted its position in Abivax by 2,561.0% during the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after acquiring an additional 4,293,606 shares during the period. Darwin Global Management Ltd. acquired a new position in Abivax during the 3rd quarter worth $263,698,000. Paradigm Biocapital Advisors LP acquired a new position in Abivax during the 3rd quarter worth $132,800,000. TCG Crossover Management LLC boosted its position in Abivax by 17.4% during the 3rd quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock worth $603,774,000 after acquiring an additional 1,055,000 shares during the period. Finally, Westfield Capital Management Co. LP acquired a new position in Abivax during the 4th quarter worth $136,199,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ABVX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a research report on Monday, April 20th. Oddo Bhf reiterated an “outperform” rating on shares of Abivax in a research report on Thursday, April 9th. Wolfe Research set a $136.00 price target on Abivax in a research report on Wednesday, June 3rd. Citizens Jmp boosted their price target on Abivax from $131.00 to $187.00 and gave the stock a “market outperform” rating in a research report on Tuesday, June 2nd. Finally, Jefferies Financial Group lowered Abivax from a “buy” rating to a “hold” rating and reduced their price target for the stock from $160.00 to $90.00 in a research report on Tuesday, June 2nd. Twelve analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Abivax presently has an average rating of “Moderate Buy” and an average target price of $130.08.

Abivax Stock Down 4.6%

Shares of Abivax stock opened at $98.03 on Thursday. Abivax SA Sponsored ADR has a fifty-two week low of $5.69 and a fifty-two week high of $148.83. The business has a fifty day simple moving average of $116.59 and a 200-day simple moving average of $119.41. The firm has a market cap of $7.81 billion, a price-to-earnings ratio of -18.82 and a beta of 0.69.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.23. The business had revenue of $1.56 million during the quarter, compared to analyst estimates of $0.40 million. Analysts anticipate that Abivax SA Sponsored ADR will post -3.4 earnings per share for the current fiscal year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.